Navigation Links
European Journal of Heart Failure publishes new randomized controlled clinical study of RESPeRATE
Date:9/28/2011

Lod, Israel. September 27th, 2011 InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced that European Journal of Heart Failure, a peer reviewed medical journal of the European Society of Cardiology, published the results of a 72-patients, randomized, controlled study which demonstrated that deviceguided respiratory modulation with RESPeRATE applied at the home setting can significantly relieve symptoms of heart failure in elderly patients.

Chronic heart failure (CHF) affects about 5 million patients in the U.S. alone. It is the most widespread cause of hospitalization of patients over 65, with over 1 million hospitalizations every year. The total cost of treating the disease is estimated at $33 billion annually. About 91% of CHF sufferers have a medical history involving hypertension.

The study was conducted by Inger Ekman, MD, Professor of Medicine, Institute of Health and Care Sciences, the Sahlgrenska Academy, University of Gothenburg, Sweden with funding from the Swedish Heart Lung Foundation. It was found that after 4 weeks of twice daily 20 minute at-home treatment sessions with RESPeRATE, patients, who modified the breathing as directed by the device , demonstrated a reduction in the severity of CHF measured by New York Heart Association (NYHA) classification, and in dyspnea (shortness of breath) that is the major reason for seeking care in the CHF population. The observed reduction was significant by both its absolute mean and in comparison with control group and/or with patients, who didn't modify breathing as directed by the device.

"CHF is disabling and leads to decreased quality of life, frequent hospitalizations and poor survival. The patient's subjective response to the condition is associated with symptoms that reflect physical aspects as well as integrated aspects of lifestyle, anxiety, depression, and expectations of the patient. The device-guided respiratory modulation provided by the RESPeRATE might have the potential to relieve symptoms of heart failure in outpatients by changing their Device-guided respiratory modulation have the potential to relieve symptoms of heart failure in outpatients by changing their breathing pattern" said Prof. Ekman.

Results are consistent with those published last year in Circulation Heart Failure by Gianfranco Parati, Professor of Medicine from St. Luca Hospital, in Milano and his colleagues. That randomized controlled study with similar use of RESPeRATE at home over 8 weeks is feasible in patients with heart failure and systolic dysfunction and demonstrated significant improvement in clinically relevant parameters for, including CHF severity; left ventricular ejection fraction and pulmonary pressure and function.

"The positive effect of the RESPeRATE on CHF patients reported by these independent studies expand the growing body of scientific evidence that already has proven RESPeRATE as a clinically valid treatment for hypertension," said Erez Gavish, President and CEO of InterCure. "We plan to continue exploring the potential of RESPeRATE and our patented device-guided respiratory modulation technology to benefit patients with other cardiovascular diseases."

RESPeRATE is the only FDA-cleared, CE-marked device indicated for the adjunctive treatment of hypertension. RESPeRATE's clinical efficacy in lowering blood pressure has been validated in 10 separate published studies and 200,000 units have been sold to consumers. RESPeRATE has not been cleared for use in the treatment of heart failure in the United States, European Union or elsewhere.


'/>"/>

Contact: Tom Kirwan
tkirwan@intercure.com
347-528-7734
InterCure
Source:Eurekalert

Related medicine news :

1. Media have less than 3 weeks to register for the European Multidisciplinary Cancer Congress 2011
2. Treatment of rectal cancer varies enormously between different European countries
3. 2011 European Muldisciplinary Cancer Congress abstracts online Sept. 12
4. The first European registry to evaluate the real-life epidemiology of atrial fibrillation ablation
5. Americans No Longer Outliving Europeans: Study
6. The only European researcher to win this years Early Career Bayer Hemophilia Award is Portuguese
7. Research reveals that 10 percent of middle-aged Europeans are on antidepressants
8. Several methods for early diagnosis of Alzheimers disease developed by European scientists
9. Officials: U.S. Not Affected by European E. Coli Outbreak
10. European Society of Human Reproduction and Embryology Annual Meeting July 3-6, 2011, Stockholm
11. Clinical trials for new Alzheimers disease treatment to be awarded European Commission €6m funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, today announced ... to the cloud. Cirracore provides a secure VMware® vCloud Air based cloud ... Transformation Solutions (TSL Partners) provides a full range of services from planning, ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... On January ... family scheduled an appointment after they noticed their furnace not producing any heat. Shortly ... heat exchanger. The cracked heat exchanger was leaking dangerous levels of carbon monoxide into ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
(Date:2/9/2016)... ... February 09, 2016 , ... ZipHearing.com is ... to affordable hearing aids , increase industry transparency, and promote awareness of ... States. , “For the average consumer, the hearing aid industry is esoteric and ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... N.Y., Feb. 9, 2016  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... debridement, cosmetic surgery, laparoscopic surgery and other surgical ... quarter and the first half of fiscal year ... --> --> Highlights for ...
(Date:2/9/2016)... -- Insulet Corporation (NASDAQ: PODD ) (Insulet or the Company), ... its OmniPod ® Insulin Management System, today ... to Insulet,s Board of Directors. With his appointment, the Board ... independent. --> --> Mr. ... and a deep knowledge of accounting, financial reporting and internal ...
(Date:2/9/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... its fourth quarter and full year 2015 financial ... therapeutic genome editing," said Edward Lanphier, Sangamo,s president ... (ZFN) technology leads the therapeutic genome editing field ... to move our ground-breaking genome editing programs through ...
Breaking Medicine Technology: